Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Infanrix Hexa

Infanrix Hexa

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Infanrix Hexa

38 trials tracked of Infanrix Hexa: 29 in phase 3 or 4 and 15 with published results. The most-cited published study has 375 citations.

38Trials tracked
29Phase 3 & 4
0Recruiting
15With published results
Phase distribution
Phase 4 6 Phase 3 23 Phase 2 9
  1. Phase 3 Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A Completed · 375 cited
  2. Phase 3 Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine. Completed · 271 cited
  3. Phase 3 Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib Completed · 134 cited
  4. Phase 3 Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine Completed · 68 cited
  5. Phase 3 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008) Completed · 42 cited
  6. Phase 3 Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants Completed · 42 cited
Show 32 more trials
  1. Phase 3 Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007) Completed · 34 cited
  2. Phase 4 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed · 28 cited
  3. Phase 3 Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025) Completed · 26 cited
  4. Phase 4 Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment Completed · 24 cited
  5. Phase 3 Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines Completed · 17 cited
  6. Phase 3 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed · 13 cited
  7. Phase 4 Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed · 12 cited
  8. Phase 4 Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Completed · 10 cited
  9. Phase 3 Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam Completed · 8 cited
  10. Phase 4 Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® Completed
  11. Phase 4 Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed
  12. Phase 3 Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule Completed
  13. Phase 3 Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants Completed
  14. Phase 3 Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine Completed
  15. Phase 3 Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine Completed
  16. Phase 3 Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age Completed
  17. Phase 3 Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines Completed
  18. Phase 3 Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC Completed
  19. Phase 3 Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Completed
  20. Phase 3 Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ Completed
  21. Phase 3 Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age Completed
  22. Phase 3 Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age Completed
  23. Phase 3 COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine Completed
  24. Phase 2 Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age Completed
  25. Phase 2 Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants Completed
  26. Phase 2 Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Completed
  27. Phase 2 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age Completed
  28. Phase 2 Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Completed
  29. Phase 2 Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine Completed
  30. Phase 2 Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose Completed
  31. Phase 2 Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants Completed
  32. Phase 2 Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule Completed

Showing the 38 most-cited and recently-updated of 38 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.